Neurocrine Biosciences (NBIX) Price Target Raised to $100.00 at JPMorgan Chase & Co.

Neurocrine Biosciences (NASDAQ:NBIX) had its target price boosted by JPMorgan Chase & Co. from $79.00 to $100.00 in a research report released on Wednesday morning. JPMorgan Chase & Co. currently has an overweight rating on the stock.

NBIX has been the subject of a number of other research reports. Oppenheimer set a $100.00 price target on Neurocrine Biosciences and gave the stock a buy rating in a research report on Wednesday. Barclays reaffirmed an overweight rating and issued a $100.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday. BidaskClub raised Neurocrine Biosciences from a buy rating to a strong-buy rating in a research report on Wednesday, January 31st. Citigroup reaffirmed a buy rating and issued a $79.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Finally, Leerink Swann reaffirmed an outperform rating and issued a $83.00 price target (up previously from $72.00) on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. One investment analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $89.53.

Neurocrine Biosciences (NASDAQ NBIX) traded up $1.69 on Wednesday, reaching $85.38. The company had a trading volume of 1,678,700 shares, compared to its average volume of 1,016,547. Neurocrine Biosciences has a 52-week low of $39.21 and a 52-week high of $91.82. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Tuesday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.11). The company had revenue of $94.52 million during the quarter, compared to analysts’ expectations of $94.00 million. During the same period last year, the firm posted ($0.51) earnings per share. analysts predict that Neurocrine Biosciences will post 0.61 earnings per share for the current year.

In related news, insider Darin Lippoldt sold 6,279 shares of the business’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $75.04, for a total transaction of $471,176.16. Following the completion of the transaction, the insider now owns 19,436 shares of the company’s stock, valued at approximately $1,458,477.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Haig P. Bozigian sold 1,625 shares of the business’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $79.12, for a total value of $128,570.00. The disclosure for this sale can be found here. Insiders have sold a total of 337,950 shares of company stock valued at $26,613,876 in the last three months. 4.80% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Crow Point Partners LLC acquired a new position in shares of Neurocrine Biosciences during the 4th quarter worth about $145,000. American International Group Inc. acquired a new position in shares of Neurocrine Biosciences during the 4th quarter worth about $161,000. M&T Bank Corp acquired a new position in shares of Neurocrine Biosciences during the 4th quarter worth about $202,000. Mission Wealth Management LP acquired a new position in shares of Neurocrine Biosciences during the 4th quarter worth about $204,000. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Neurocrine Biosciences by 7.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after purchasing an additional 193 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: “Neurocrine Biosciences (NBIX) Price Target Raised to $100.00 at JPMorgan Chase & Co.” was first reported by Week Herald and is owned by of Week Herald. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://weekherald.com/2018/02/15/neurocrine-biosciences-nbix-price-target-raised-to-100-00-at-jpmorgan-chase-co.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply